Zum Inhalt

Brief review of the mRNA vaccines COVID-19

  • Zur Zeit gratis
  • 01.05.2021
  • SARS-CoV-2
  • Short Communication
Erschienen in:

Abstract

The global COVID-19 pandemic continues to claim victims worldwide, representing a health and socioeconomic challenge with few precedents in human history. The therapeutic agents used to treat COVID-19 infection are mostly aimed at avoiding the most serious complications and organ damage that in a percentage of cases can be fatal. Recently, the first COVID-19 vaccines have been authorised, starting a massive vaccination campaign worldwide. The COVID-19 vaccines authorized or under testing use different methods of action such as mRNA, DNA vaccine, viral vector, protein subunit, and virus inactivated immunization strategies. The mRNA vaccines are the first authorised vaccines with this new method of action, initiating a new era of preventive medicine. To date, data indicate that they may be effective against the newly identified SARS-CoV-2 variants. Short-term studies indicated an acceptable safety profile but long-term immunity as well as safety is not yet available. In this article, we briefly describe mRNA vaccines and highlight some aspects yet to be fully defined.
Titel
Brief review of the mRNA vaccines COVID-19
Verfasst von
Antonio Vitiello
Francesco Ferrara
Publikationsdatum
01.05.2021
Verlag
Springer International Publishing
Schlagwörter
SARS-CoV-2
COVID-19
Erschienen in
Inflammopharmacology / Ausgabe 3/2021
Print ISSN: 0925-4692
Elektronische ISSN: 1568-5608
DOI
https://doi.org/10.1007/s10787-021-00811-0
Dieser Inhalt ist nur sichtbar, wenn du eingeloggt bist und die entsprechende Berechtigung hast.